NCT00041795
Completed
Phase 2
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Neotrofin to Treat Patients With Sensory or Motor Neuropathy Caused by Chemotherapy for Cancer
NeoTherapeutics6 sites in 1 country50 target enrollmentJanuary 2002
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Peripheral Nervous System Diseases
- Sponsor
- NeoTherapeutics
- Enrollment
- 50
- Locations
- 6
- Status
- Completed
- Last Updated
- 20 years ago
Overview
Brief Summary
This study will assess the safety and efficacy of Neotrofin in treating the peripheral neuropathy that results from chemotherapy for cancer.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (6)
Loading locations...
Similar Trials
Completed
Phase 3
Treatment of Peripheral Neuropathy in Patients With DiabetesDiabetic NeuropathiesDiabetes MellitusNCT00044421Eli Lilly and Company400
Completed
Not Applicable
Evaluation of the The Neuromodulation System for the Treatment of Overactive Bladder SymptomsOveractive BladderNCT04999657Medtecx Co Ltd.109
Completed
Phase 2
Neurotropin Treatment of FibromyalgiaFibromyalgiaNCT00366535National Institute of Nursing Research (NINR)56
Terminated
Phase 1
SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN)Chemotherapy-induced Peripheral Neuropathy (CIPN)NCT05435742Sonnet BioTherapeutics9
Recruiting
Phase 2
Randomized controlled trial for peripheral neuropathy comparing weekly Paclitaxel followed by FEC100 with Eribulin Mesilate followed by FEC100 as neoadjuvant chemotherapy in primary breast cancer patients.Operable early Breast CancerJPRN-UMIN000012817JONIE Study Group230